Literature DB >> 16804086

Common variants of the endothelial nitric oxide synthase gene and the risk of coronary heart disease among U.S. diabetic men.

Cuilin Zhang1, Ruy Lopez-Ridaura, David J Hunter, Nader Rifai, Frank B Hu.   

Abstract

Endothelial nitric oxide synthase (eNOS) gene represents a promising candidate gene for coronary heart disease (CHD) because of its impact on eNOS activity. We systematically examined the associations of eight variants of the eNOS gene (two potentially functional variants [-786T>C and Glu298Asp] and six tagging single nucleotide polymorphisms) with CHD risk in a large cohort of diabetic patients. Among 861 diabetic men (>97% Caucasian) from the Health Professionals Follow-Up Study, 220 developed CHD, and 641 men without cardiovascular disease were used as control subjects. Genotype distributions of -786T>C and Glu298Asp polymorphisms were not significantly different between case and control subjects. CHD risk was significantly higher among men with the variant allele at the rs1541861 locus (intron 8 A/C) than men without it (adjusted odds ratio 1.5 [95% confidence interval 1.1-2.1]). Moreover, among control subjects, plasma soluble vascular cell adhesion molecule concentrations were significantly higher among carriers of this allele (P 0.019) and carriers of the variant allele of the -786T>C (P 0.010), or the Glu298Asp polymorphism (P 0.002), compared with noncarriers. In conclusion, our data suggested that -786T>C, Glu298Asp, and an intron 8 polymorphism of the eNOS gene are potentially involved in the atherogenic pathway among U.S. diabetic men.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804086     DOI: 10.2337/db05-1535

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  7 in total

Review 1.  The genetics of vascular complications in diabetes mellitus.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

2.  Association of endothelial nitric oxide synthase polymorphisms with coronary artery disease in Korean individuals with or without diabetes mellitus.

Authors:  Jeehyeon Bae; In Jai Kim; Seung Ho Hong; Jung Hoon Sung; Sang Wook Lim; Dong Hoon Cha; Yong Wook Cho; Doyeun Oh; Nam Keun Kim
Journal:  Exp Ther Med       Date:  2010-07-01       Impact factor: 2.447

3.  NOS3 rs1799983 and rs2070744 polymorphisms and their association with advanced chronic kidney disease and coronary heart disease in Canarian population with type 2 diabetes.

Authors:  M Boronat; A Tugores; P Saavedra; P Garay; E Bosch; D Lorenzo; A Ibarra; C García-Cantón
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

4.  Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in Turkish patients with ischemic stroke.

Authors:  Baburhan Guldiken; Tammam Sipahi; Sibel Guldiken; Sedat Ustundag; Metin Budak; Nilda Turgut; Hulya Ozkan
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

5.  Role of nitric oxide synthase gene intron 4 and exon 7 polymorphisms in obstructive sleep apnea syndrome.

Authors:  Yildirim A Bayazit; Metin Yilmaz; Emin Erdal; Tansu Ulukavak Ciftci; Alper Ceylan; Oguz Kokturk; Fatih Celenk; Yusuf K Kemaloglu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-07-24       Impact factor: 2.503

6.  Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease.

Authors:  Ai Yuan Zhang; Xiang Wu Ji; Ai Juan Zhang; Li Xue Guan; Jing Huang; Jing Xian Wang
Journal:  Cardiol Res       Date:  2010-11-20

7.  Association of the 894G>T polymorphism in the endothelial nitric oxide synthase gene with risk of acute myocardial infarction.

Authors:  George K Andrikopoulos; Dimitris K Grammatopoulos; Stylianos E Tzeis; Sevasti I Zervou; Dimitris J Richter; Michalis N Zairis; Elias J Gialafos; Dimitris C Sakellariou; Stefanos G Foussas; Antonis S Manolis; Christodoulos I Stefanadis; Pavlos K Toutouzas; Edward W Hillhouse
Journal:  BMC Med Genet       Date:  2008-05-21       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.